{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:22:47Z","timestamp":1740144167690,"version":"3.37.3"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["00064203","0098892"],"award-info":[{"award-number":["00064203","0098892"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]},{"name":"OP VVV ENOCH","award":["CZ.02.1.01\/0.0\/0.0\/16_019\/0000868"],"award-info":[{"award-number":["CZ.02.1.01\/0.0\/0.0\/16_019\/0000868"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s40272-021-00439-1","type":"journal-article","created":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T17:03:20Z","timestamp":1615482200000},"page":"183-194","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Is It Useful to Monitor Thiopurine Metabolites in Pediatric Patients with Crohn\u2019s Disease on Combination Therapy? A Multicenter Prospective Observational Study"],"prefix":"10.1007","volume":"23","author":[{"given":"Kristyna","family":"Pospisilova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jitka","family":"Siroka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Karaskova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ondrej","family":"Hradsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tereza","family":"Lerchova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristyna","family":"Zarubova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivana","family":"Copova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucie","family":"Gonsorcikova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Velganova-Veghova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irena","family":"Francova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lubor","family":"Urbanek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milos","family":"Geryk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladimir","family":"Mihal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiri","family":"Bronsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,11]]},"reference":[{"issue":"15","key":"439_CR1","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","volume":"362","author":"JF Colombel","year":"2010","unstructured":"Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. Infliximab, azathioprine, or combination therapy for Crohn\u2019s disease. N Engl J Med. 2010;362(15):1383\u201395.","journal-title":"N Engl J Med."},{"issue":"7","key":"439_CR2","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1053\/j.gastro.2008.03.004","volume":"134","author":"G Van Assche","year":"2008","unstructured":"Van Assche G, Magdelaine-Beuzelin C, D\u2019Haens G, Baert F, Noman M, Vermeire S, et al. Withdrawal of immunosuppression in Crohn\u2019s disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterol. 2008;134(7):1861\u20138.","journal-title":"Gastroenterol."},{"issue":"3","key":"439_CR3","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2036.2009.04027.x","volume":"30","author":"GR Lichtenstein","year":"2009","unstructured":"Lichtenstein GR, Diamond RH, Wagner CL, Fasanmade AA, Olson AD, Marano CW, Johanns J, et al. Clinical trial: benefits and risks of immunomodulators and maitenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther. 2009;30(3):210\u201326.","journal-title":"Aliment Pharmacol Ther."},{"issue":"5","key":"439_CR4","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1097\/MPG.0000000000000684","volume":"60","author":"J Kierkus","year":"2015","unstructured":"Kierkus J, Iwanczak B, Wegner A, Dadalski M, Grzybowska-Chlebowczyk U, Lazowska I, et al. Monotherapy with infliximab versus combination therapy in the maintenance of clinical remission in children with moderate to severe Crohn disease. J Pediatr Gastroenterol Nutr. 2015;60(5):580\u20135.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"439_CR5","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1053\/gast.2002.32420","volume":"122","author":"MC Dubinsky","year":"2002","unstructured":"Dubinsky MC, Yang H, Hassard PV, Seidman EG, Kam LY, Abreu MT, et al. 6-MP metabolite profiles provide a biochemical explanantion for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterol. 2002;122:904\u201315.","journal-title":"Gastroenterol."},{"key":"439_CR6","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1097\/01.fpc.0000114745.08559.db","volume":"14","author":"E Schaeffeler","year":"2004","unstructured":"Schaeffeler E, Fisher C, Dierk B, Wernet D, Klaus M, Eichelbaum M, et al. Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogen. 2004;14:407\u201317.","journal-title":"Pharmacogen."},{"key":"439_CR7","first-page":"651","volume":"32","author":"RM Weinshilboum","year":"1980","unstructured":"Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Gen. 1980;32:651\u201362.","journal-title":"Am J Hum Gen."},{"issue":"4","key":"439_CR8","first-page":"951","volume":"21","author":"X Roblin","year":"2016","unstructured":"Roblin X, Williet N, Peyrin-Biroulet L. Thiopurine metabolism in the era of combotherapy. Inflamm Bowel Dis. 2016;21(4):951\u201361.","journal-title":"Inflamm Bowel Dis."},{"issue":"6","key":"439_CR9","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/j.cgh.2014.12.026","volume":"13","author":"AJ Yarur","year":"2015","unstructured":"Yarur AJ, Kubiliun MJ, Czul F, Sussman DA, Quintero MA, Jain A, et al. Concentrations of 6-thioguanine nucleotide correlate with trough levels of infliximab in patients with inflammatory bowel disease on combination therapy. Clin Gastroenterol Hepatol. 2015;13(6):1118\u201324.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"439_CR10","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1053\/j.gastro.2006.01.046","volume":"130","author":"MT Osterman","year":"2006","unstructured":"Osterman MT, Kundu R, Lichtenstein GR, Lewis JD. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterol. 2006;130:1047\u201353.","journal-title":"Gastroenterol."},{"key":"439_CR11","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1097\/01.MIB.0000439068.71126.00","volume":"20","author":"AC Moreau","year":"2014","unstructured":"Moreau AC, Paul S, Del Tedesco E, Rinaudo-Gaujous M, Baukhadra N, Genin C, et al. Association between 6-thioguanine nucleotides levels and clinical remission in inflammatory bowel disease: a meta-analysis. Inflamm Bowel Dis. 2014;20:464\u201371.","journal-title":"Inflamm Bowel Dis."},{"key":"439_CR12","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S0016-5085(00)70140-5","volume":"118","author":"MC Dubinsky","year":"2000","unstructured":"Dubinsky MC, Lamothe S, Ying Yang G, Targan SR, Sinnett D, Theoret Y, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterol. 2000;118:705\u201313.","journal-title":"Gastroenterol."},{"key":"439_CR13","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.crohns.2014.04.005","volume":"8","author":"FM Ruemmelle","year":"2014","unstructured":"Ruemmelle FM, Veres G, Kolho KL, Griffiths A, Levine A, Escher JC, et al. Consensus guidelines of ECCO\/ESPHGAN on the medical management of pediatric Crohn\u2019s disease. J Crohns Colitis. 2014;8:1179\u2013207.","journal-title":"J Crohns Colitis"},{"key":"439_CR14","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.cgh.2006.11.020","volume":"5","author":"MP Sparrow","year":"2007","unstructured":"Sparrow MP, Hande SA, Friedman S, Cao D, Hanauer SB. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin Gastroenterol Hepatol. 2007;5:209\u201314.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"439_CR15","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1046\/j.1365-2036.2002.01353.x","volume":"16","author":"A Ansari","year":"2002","unstructured":"Ansari A, Hassan C, Duley J, Marinaki A, Shobowale-Bakre EM. Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. Aliment Pharmacol Ther. 2002;16:1743\u201350.","journal-title":"Aliment Pharmacol Ther."},{"issue":"6","key":"439_CR16","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1097\/MPG.0000000000000239","volume":"58","author":"A Levine","year":"2014","unstructured":"Levine A, Koletzko S, Turner D, Escher JC, Cucchiara S, de Ridder L, et al. ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr. 2014;58(6):795\u2013806.","journal-title":"J Pediatr Gastroenterol Nutr."},{"issue":"1","key":"439_CR17","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/ibd.21649","volume":"18","author":"D Turner","year":"2012","unstructured":"Turner D, Griffiths AM, Walters TD, Seah T, Markowitz J, Pfefferkorn M, et al. Mathematical weighting of the pediatric Crohn\u2019s disease activity index (PCDAI) and comparison with its other short versions. Inflamm Bowel Dis. 2012;18(1):55\u201362.","journal-title":"Inflamm Bowel Dis."},{"issue":"4","key":"439_CR18","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1097\/01.mpg.0000183350.46795.42","volume":"41","author":"J Hyams","year":"2005","unstructured":"Hyams J, Markowitz J, Otley A, Rosh J, Mack D, Bousvaros A, et al. Evaluation of the pediatric Crohn disease activity index: a prospective multicenter experience. J Pediatr Gastroenterol Nutr. 2005;41(4):416\u201321.","journal-title":"J Pediatr Gastroenterol Nutr."},{"issue":"3","key":"439_CR19","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1093\/clinchem\/44.3.551","volume":"44","author":"T Dervieux","year":"1998","unstructured":"Dervieux T, Boulieu R. Simultaneous determination of 6-thioguanine and methyl-mercaptopurine nucleotides of azathioprine in red blood cells by HPLC. Clin Chem. 1998;44(3):551\u20135.","journal-title":"Clin Chem"},{"key":"439_CR20","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jpba.2008.10.045","volume":"49","author":"AF Hawwa","year":"2009","unstructured":"Hawwa AF, Millership JS, Colier PS, McElnay JC. Development and validation of HPLC method for the rapid and simultaneous determination of 6-mercaptopurine and four of its metabolites in plasma and red blood cells. J Pharmaceut Biomed Anal. 2009;49:401\u20139.","journal-title":"J Pharmaceut Biomed Anal."},{"issue":"11","key":"439_CR21","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1373\/clinchem.2005.050831","volume":"51","author":"T Dervieux","year":"2005","unstructured":"Dervieux T, Meyer G, Barham R, Matsutani M, Barry M, Boulieu R, et al. Liquid chromatography-tandem mass spectrometry analysis of erythrocyte thiopurine nucleotides and effect of thiopurine methyltransferase gene variants on these metabolited in patients receiving azathioprine\/6-mercaptopurine therapy. Clin Chem. 2005;51(11):2074\u201384.","journal-title":"Clin Chem."},{"issue":"15","key":"439_CR22","doi-asserted-by":"publisher","first-page":"e3326","DOI":"10.1097\/MD.0000000000003326","volume":"95","author":"Z Fangbin","year":"2016","unstructured":"Fangbin Z, Xiang G, Liang D, Hui L, Xueding W, et al. Prospective evaluation of pharmacogenomics and metabolite measurements upon azathioprine therapy in inflammatory bowel disease. Medicine. 2016;95(15):e3326.","journal-title":"Medicine"},{"issue":"7","key":"439_CR23","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1053\/j.gastro.2015.02.031","volume":"148","author":"N Vande Casteele","year":"2015","unstructured":"Vande Casteele N, Ferrante M, Van Assche G, Ballet V, Compernolle G, Van Steen K, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterol. 2015;148(7):1320\u20139.","journal-title":"Gastroenterol."},{"issue":"11","key":"439_CR24","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1097\/MIB.0000000000000156","volume":"20","author":"BP Vaughn","year":"2014","unstructured":"Vaughn BP, Martinez-Vazquez M, Patwardhan VR, Moss AC, Sandborn WJ, Cheifetz AS. Proactive therapeutic concentration monitoring of infliximab may improve outcomes for patients with inflammatory bowel disease: results from a pilot observational study. Inflamm Bowel Dis. 2014;20(11):1996\u20132003.","journal-title":"Inflamm Bowel Dis."},{"issue":"11","key":"439_CR25","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1093\/ecco-jcc\/jjy111","volume":"12","author":"K van Hoeve","year":"2018","unstructured":"van Hoeve K, Dreesen E, Hoffman I, Van Assche G, Ferrante M, Gils A, et al. Higher infliximab trough levels are associated with better outcome in paediatric patients with inflammatory bowel disease. J Crohn Colitis. 2018;12(11):1316\u201325.","journal-title":"J Crohn Colitis."},{"issue":"3","key":"439_CR26","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1053\/j.gastro.2017.07.032","volume":"153","author":"JD Feuerstein","year":"2017","unstructured":"Feuerstein JD, Nguyen GC, Kupfer SS, Falck-Ytter Y, Singh S. American gastroenterological association institute guideline on therapeutic drug monitoring in inflammatory bowel disease. Gastroenterol. 2017;153(3):827\u201334.","journal-title":"Gastroenterol."},{"issue":"2","key":"439_CR27","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/apt.14106","volume":"46","author":"X Roblin","year":"2017","unstructured":"Roblin X, Boschetti G, Williet N, Nancey S, Marotte H, Berger A, et al. Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trial. Aliment Pharmacol Ther. 2017;46(2):142\u20139.","journal-title":"Aliment Pharmacol Ther."},{"issue":"7","key":"439_CR28","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1111\/apt.15179","volume":"49","author":"D Drobne","year":"2019","unstructured":"Drobne D, Kurent T, Golob S, \u0160vegl P, Rajar P, Han\u017eel J, et al. Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease. Aliment Pharmacol Ther. 2019;49(7):880\u20139.","journal-title":"Aliment Pharmacol Ther."},{"issue":"10","key":"439_CR29","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1016\/j.cgh.2015.04.010","volume":"13","author":"V Grossi","year":"2015","unstructured":"Grossi V, Lerer T, Griffiths A, LeLeiko N, Cabrera J, Otley A, et al. Concomitant use if immunomodulators affects the durability of inflixima therapy in children with Crohn\u2019s disease. Clin Gastroenterol Hepatol. 2015;13(10):1748\u201356.","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"2","key":"439_CR30","doi-asserted-by":"publisher","first-page":"121","DOI":"10.5223\/pghn.2020.23.2.121","volume":"23","author":"H van Rheen","year":"2020","unstructured":"van Rheen H, van Rheen PF. Long-term efficacy of anti-tumor necrosis factor agents in pediatric luminal Crohn\u2019s disease: a systemic review or real-world evidence studies. Pediatr Gastroenterol Hepatol Nutr. 2020;23(2):121\u201331.","journal-title":"Pediatr Gastroenterol Hepatol Nutr."},{"issue":"4","key":"439_CR31","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1097\/MPG.0000000000002436","volume":"69","author":"O Hradsky","year":"2019","unstructured":"Hradsky O, Potuznikova K, Siroka J, Lerchova T, Urbanek L, Mihal V, et al. Prediction of thiopurine metabolite levels based on hematological and biochemical parameters. J Pediatr Gastroenterol Nutr. 2019;69(4):e105\u201310.","journal-title":"J Pediatr Gastroenterol Nutr."},{"issue":"2","key":"439_CR32","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1097\/MPG.0000000000001672","volume":"66","author":"JC deBruyn","year":"2018","unstructured":"deBruyn JC, Jacobson K, El-Matary W, Carroll M, Wine E, Wrobel I, et al. Long-term Outcomes of Infliximab Use for Pediatric Crohn Disease: A Canadian Multicenter Clinical Practice Experience. J Pediatr Gastroenterol Nutr. 2018;66(2):268\u201373.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"12","key":"439_CR33","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1007\/s00431-020-03750-0","volume":"179","author":"MME Jongsma","year":"2020","unstructured":"Jongsma MME, Winter DA, Huynh HQ, Norsa L, Hussey S, Kolho K-L, et al. Infliximab in young paediatric IBD patients: it is all about the dosing. Eur J Pediatr. 2020;179(12):1935\u201344.","journal-title":"Eur J Pediatr."},{"issue":"8","key":"439_CR34","doi-asserted-by":"publisher","first-page":"645","DOI":"10.2165\/00003088-200746080-00002","volume":"46","author":"U Klotz","year":"2007","unstructured":"Klotz U, Teml A, Schwab M. Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet. 2007;46(8):645\u201360.","journal-title":"Clin Pharmacokinet."},{"issue":"8","key":"439_CR35","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1007\/s40262-017-0627-0","volume":"57","author":"A Hemperly","year":"2018","unstructured":"Hemperly A, Vande CN. Clinical pharmacokinetics and pharmacodynamics of infliximab in the treatment of inflammatory bowel disease. Clin Pharmacokinet. 2018;57(8):929\u201342.","journal-title":"Clin Pharmacokinet."},{"issue":"4","key":"439_CR36","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/clpt.2011.328","volume":"91","author":"I Ord\u00e1s","year":"2012","unstructured":"Ord\u00e1s I, Mould DR, Feagan BG, Sandborn WJ. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther. 2012;91(4):635\u201346.","journal-title":"Clin Pharmacol Ther."},{"issue":"4","key":"439_CR37","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1097\/MIB.0000000000001043","volume":"23","author":"JF Brandse","year":"2017","unstructured":"Brandse JF, Mould D, Smeekes O, Ashruf Y, Kuin S, Strik A, et al. A real-life population pharmacokinetic study reveals factors associated with clearance and immunogenicity of infliximab in inflammatory bowel disease. Inflamm Bowel Dis. 2017;23(4):650\u201360.","journal-title":"Inflamm Bowel Dis."},{"issue":"3","key":"439_CR38","first-page":"2230","volume":"13","author":"J Jones","year":"2015","unstructured":"Jones J, Kaplan GG, Peyrin-Biroulet L, Baidoo L, Devlin S, Melmed GY, et al. Impact of concomitant immunomodulator treatment on efficacy and safety of anti-TNF therapy in Crohn\u2019s disease: a meta-analysis of placebo controlled trials with individual patient-level data. Clin Gastroenterol Hepatol. 2015;13(3):2230\u201340.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"439_CR39","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/ibd.20798","volume":"15","author":"KA Hommel","year":"2009","unstructured":"Hommel KA, Davis CM, Baldassanp RN. Objective versus Subjective Assesment of Oral Medication Adherence in Pediatric Inflammatory Bowel Disease. Inflamm Bowel Dis. 2009;15:589\u201393.","journal-title":"Inflamm Bowel Dis."},{"issue":"6","key":"439_CR40","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.crohns.2010.06.005","volume":"4","author":"O Pozler","year":"2010","unstructured":"Pozler O, Chl\u00e1dek J, Mal\u00fd J, Hroch M, D\u011bdek P, Ber\u00e1nek M, et al. Steady-state of azathioprine during initiation treatement of pediatric inflammatory bowel disease. J Crohns Colitis. 2010;4(6):623\u20138.","journal-title":"J Crohns Colitis."},{"key":"439_CR41","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1002\/ibd.20522","volume":"14","author":"RM Rahhal","year":"2008","unstructured":"Rahhal RM, Bishop WP. Initial clinical experience with allopurinol-thiopurine combination therapy in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2008;14:1678\u201382.","journal-title":"Inflamm Bowel Dis."},{"key":"439_CR42","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.crohns.2010.03.004","volume":"14","author":"ME Gerich","year":"2010","unstructured":"Gerich ME, Quiros JA, Marcin JP, Tennyson L, Henthorn M, Prindiville TP. A prospective evaluation of the impact of allopurinol in pediatric and adult IBD patients with preferentioal metabolism of 6-mercaptopurine to 6-methylmercaptopurine. J Crohns Colitis. 2010;14:546\u201352.","journal-title":"J Crohns Colitis."},{"key":"439_CR43","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1111\/apt.14571","volume":"47","author":"AB Friedman","year":"2018","unstructured":"Friedman AB, Brown SJ, Bampton P, Barclay ML, Chung A, Macrae FA, et al. Randomised clinical trial: efficacy, safety and dosage of adjunctive allopurinol i azathioprine\/mercaptopurine nonresponders (AAA Study). Aliment Pharmacol Ther. 2018;47:1092\u2013102.","journal-title":"Aliment Pharmacol Ther."}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-021-00439-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-021-00439-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-021-00439-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T00:16:30Z","timestamp":1675037790000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-021-00439-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["439"],"URL":"https:\/\/doi.org\/10.1007\/s40272-021-00439-1","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"type":"print","value":"1174-5878"},{"type":"electronic","value":"1179-2019"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"19 February 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by Ministry of Health (Czech Republic) funding for the conceptual development of research organizations [00064203, University Hospital Motol, Prague, Czech Republic, and 0098892, University Hospital, Olomouc, Czech Republic], and the OP VVV ENOCH [CZ.02.1.01\/0.0\/0.0\/16_019\/0000868].","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Pospisilova K: lectures\/congress fees\/consultancy (outside submitted work)\u2014MSD, Nutricia, Nestl\u00e9 and Mead Johnsons; Karaskova E: lectures\/congress fees\/consultancy (outside submitted work)\u2014MSD, AbbVie, Nutricia, and Nestl\u00e9; Hradsky O: lectures\/congress fees\/consultancy (outside submitted work)\u2014MSD, AbbVie, Nutricia, Nestl\u00e9, Ferring, and Falk; Lerchova T: lectures\/congress fees\/consultancy (outside submitted work)\u2014Nutricia, Ferring and Biocodex; Zarubova K: lectures\/congress fees\/consultancy (outside submitted work)\u2014Nutricia and Nestl\u00e9; Velganova-Veghova M: congress fees\/consultancy (outside submitted work)\u2014MSD, AbbVie, Nutricia, and Nestl\u00e9; Bronsky J: lectures\/congress fees\/consultancy (outside submitted work)\u2014MSD, AbbVie, Nutricia, Nestl\u00e9, Ferring, Biocodex, and Walmark; Gonsorcikova L, Francova I, Geryk M, Copova I, Mihal V, Siroka J, and Urbanek L report no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure of potential conflicts of interest"}},{"value":"The protocol for the observational study was approved by the Ethics Committees of the University Hospital Motol and the 2nd Medical Faculty of Charles University in Prague.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from legal guardians before study enrollment.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Non applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The study has been registered retrospectively in the ENCePP registry (encepp.eu), it can be found under the registration number EUPAS38918. Registered on 12 January 2021.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Study registration"}},{"value":"The datasets analyzed during the current study are available from the corresponding author on reasonable request.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"The code is available from the corresponding author on reasonable request.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"PK: study design, literature search, data collection, patient recruitment, thiopurine metabolite measurement, data analysis, manuscript writing; SJ: data collection, thiopurine metabolite measurement and laboratory supervision, manuscript critical revision; KE: data collection, patient recruitment, manuscript critical revision; HO: study design, data analysis and interpretation, manuscript critical revision; LT: study design, data collection, patient recruitment, manuscript critical revision, ZK: data collection, patient recruitment, manuscript critical revision; CI: data collection, patient recruitment, manuscript critical revision; GL: data collection, patient recruitment, manuscript critical revision; V-VM: data collection, patient recruitment, manuscript critical revision; FI: data collection, infliximab levels and antibodies measurement supervision, manuscript critical revision; UL: thiopurine metabolite measurement\u2014method optimization, data collection, manuscript critical revision; GM: data collection, patient recruitment, manuscript critical revision; Mihal V: data collection, supervision, manuscript critical revision; BJ: study design and supervision, literature search, manuscript writing. All authors read and approved the final manuscript.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}